BONUS ZERTIFIKAT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 01:15:14 15/06/2024 am IST | ||
| 100.3 EUR | +0.93% |
|
| Current month | +5.70% | ||
| 1 month | +7.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 100.3 | +0.91% |
| 13/24/13 | 99.38 | -0.87% |
| 12/24/12 | 100.2 | +1.29% |
| 11/24/11 | 98.97 | -1.55% |
| 10/24/10 | 100.5 | +0.56% |
Real-time Boerse Frankfurt Warrants
Last update June 15, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW9132 |
| ISIN | DE000SW91325 |
| Date issued | 08/05/2024 |
| Strike | 950 kr |
| Maturity | 20/09/2024 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 87.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 101.2 € |
|---|---|
| Lowest since issue | 90.34 € |
| Spread | 1.07 € |
| Spread % | 1.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
